The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA.
Ohlschläger
Peter
P
Department of Immunology, University of Constance, 78457 Constance, Germany. peter.oehlschlaeger@uni-konstanz.de
Spies
Elmar
E
Alvarez
Gerardo
G
Quetting
Michael
M
Groettrup
Marcus
M
D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002460:Cell Line; D018899:CpG Islands; D018274:Electroporation; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D050725:Papillomavirus E7 Proteins / Q000235:genetics / Q000276:immunology*; D010957:Plasmids; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000502:physiology*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D019496:Cancer Vaccines; D050725:Papillomavirus E7 Proteins; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16